GHRH analog
/GHRH analog (G-H-R-H)/
Also known as: growth hormone-releasing hormone analog, GHRH peptide
Definition
GHRH (growth hormone-releasing hormone) analogues are peptide compounds engineered to resemble or enhance the activity of the naturally occurring GHRH hormone. The endogenous GHRH is a 44-amino-acid peptide produced by the hypothalamus that binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, triggering the synthesis and secretion of growth hormone. GHRH analogues are modified versions designed to increase stability, improve receptor selectivity, or enhance potency. Research has focused on characterizing their receptor binding properties, their effects on GH pulse patterns, and their potential interactions with other hormonal axes such as gonadotropins and prolactin.
The endogenous GHRH is released in pulses, creating characteristic oscillations in growth hormone secretion throughout the day and night. GHRH analogues studied in research contexts have been examined for their ability to modulate these pulsatile patterns. Different structural modifications—such as amino acid substitutions, N-terminal modifications, or D-amino acid incorporation—produce analogues with varying receptor affinities and metabolic stability. These modifications influence both the onset and duration of GH-releasing activity.
GHRH analogues are often investigated in combination with other secretagogues, such as ghrelin receptor agonists, to understand synergistic or additive effects on GH secretion. Preclinical studies have explored their effects in various animal models, and clinical research has examined their pharmacodynamics and safety profiles in human subjects. The therapeutic potential for conditions characterized by GH deficiency or age-related GH decline has been a focus of regulatory and commercial development.